sharetrader
Page 1 of 15 1234511 ... LastLast
Results 1 to 15 of 219
  1. #1
    Member
    Join Date
    Oct 2013
    Posts
    124

    Default Promisia Integrative Limited (PIL)

    Previously known as the penny dreadful Savoy Equities

    Anyone going for a punt?

    http://www.stuff.co.nz/business/indu...matory-product

  2. #2
    Reincarnated Panthera Snow Leopard's Avatar
    Join Date
    Jul 2004
    Posts
    286

    Thumbs down and still a penny dreadful

    and little liquidity.

    The record date for the SPP was yesterday, so you needed to have bought on or before the 22nd.

    The 'good news' announcement was not until the afternoon of the 22nd, so at least it is difficult to say that they tried to spruik it.

    It could be the next PEB, if that can be considered as a good thing.

    Best Wishes
    Paper Tiger
    om mani peme hum

  3. #3
    The Wolf of Sharetrader
    Join Date
    Jul 2013
    Location
    On my Superyacht
    Posts
    1,283

    Default

    "We compared it to some natural, and even some synthetic, anti-inflammatory products out there and we are pretty much beating them all," Daily said.

    This statement doesn't exactly inspire much confidence...

  4. #4
    Senior Member
    Join Date
    Dec 2001
    Location
    Wellington, , New Zealand.
    Posts
    871

    Default

    PIL have done a lot of prep work over several years, and are finally looking like they might have a better mousetrap. The company has hired a new CEO who has knowledge of and connections in the US healthcare market. Who knows where this one will go, but arthritis, and inflammation generally, is a huge potential market so might be worth a punt.

    Disc, have a few, not worth much though.

  5. #5
    Senior Member
    Join Date
    Dec 2001
    Location
    Wellington, , New Zealand.
    Posts
    871

    Default

    Half year results out now. A bigger loss due to increased setting up costs. Revenue from sales almost doubled from last half year, though still quite small. Arthrem is only sold in NZ so far but a lot of work happening to develop the US market.

    Might not have recalled correctly, but I think their base product was originally trialed as a natural anti malarial and the arthritis aspect unexpectedly popped out of those trials.

    As mentioned above, hold a few, mainly to support a local Wellington initiative.

  6. #6
    Senior Member
    Join Date
    Dec 2001
    Location
    Wellington, , New Zealand.
    Posts
    871

    Default

    Announced today:

    Publication of Peer-Reviewed Research Paper on Arthrem(TM)

    Mr Malcolm Johnson, Chairman of Promisia Integrative Limited announced today the publication of a peer-reviewed scientific research paper. The paper's
    first author is the company's Principal Scientist Dr Sheena Hunt. The research paper was published by the Journal of Inflammation Research, a
    recognised and authoritative international journal.

    The published results show that the primary ingredient of Arthrem(TM), Promisia's proprietary plant extract, has potent anti-inflammatory activity
    in vitro. Concentrations as low as 0.05% completely inhibited production of the inflammatory mediator tumour necrosis factor-alpha. The extract was also
    a strong inhibitor of the cyclooxygenase (COX) inflammatory marker, prostaglandin E2.

  7. #7
    Senior Member
    Join Date
    Dec 2001
    Location
    Wellington, , New Zealand.
    Posts
    871

    Default

    Small but pretty interactive PIL annual meeting earlier this week. There was an announcement beforehand relating to a randomised, double-blind, placebo-controlled, 12 week trial at the Rheumatology Research Unit, University of Otago, which was partially funded by Callaghan Innovation. This produced statistically significant results on the benefits of Arthrem and is to be published in a peer reviewed journal. A version of the product for canine arthritis is underway - fur babies is a potentially lucrative market. The company is positioning its products as rigorously tested / trialled - rather unusual in NZ's fairly unregulated nutritional supplements market.

    Arthrem has been quietly launched in the US (arthrem.com) with the intention of selling on a subscription basis worldwide. A surprisingly small number of subscriptions is required to be profitable.
    Last edited by artemis; 29-05-2015 at 06:44 AM.

  8. #8
    Senior Member airedale's Avatar
    Join Date
    Apr 2003
    Location
    Above the high tide mark.
    Posts
    1,229

    Default

    Artemis, what is a "fur baby"? And what do you get on a "subscription basis"? Arthrem capsules? Shares?
    I assume from your name that you have a connection with Artemisia Annua.
    I have a bottle of Arthrem in my medicine cabinet. After taking it for 3 months I am not sure that it helped me. But still willing to talk about it, maybe not so willing to pay for it.

  9. #9
    Senior Member
    Join Date
    Dec 2001
    Location
    Wellington, , New Zealand.
    Posts
    871

    Default

    Quote Originally Posted by airedale View Post
    Artemis, what is a "fur baby"? And what do you get on a "subscription basis"? Arthrem capsules? Shares?
    I assume from your name that you have a connection with Artemisia Annua.
    I have a bottle of Arthrem in my medicine cabinet. After taking it for 3 months I am not sure that it helped me. But still willing to talk about it, maybe not so willing to pay for it.
    Fur baby - common name for a pet treated like one of the family. I used it rather tongue in cheek to indicate that folk with fur babies often spend big on them, as they would for a human child.

    Subscription is for capsules.

    No, my user name is complete coincidence, and relates to the Greek myth. I am a shareholder, however, and was one long before this product was even thought of.

    The Principal Scientist at PIL said the Rheumatology Research Unit was very pleased with the results.

    As I type this, another coincidence, NBR Radio is broadcasting quite a lengthy item on PIL and Arthrem.

  10. #10
    Advanced Member
    Join Date
    Aug 2012
    Posts
    1,745

    Default

    Quote Originally Posted by artemis View Post
    Fur baby - common name for a pet treated like one of the family. ....
    Aka Fur-kid.

  11. #11
    Senior Member
    Join Date
    Dec 2001
    Location
    Wellington, , New Zealand.
    Posts
    871

    Default

    Half year report to 30 June released. Link below. Projections suggest cash flow positive by end of 2016. Capital raising coming. Also coming 3 new products in the pipeline.

    Interesting that artemisia annua is the basis for the malaria treatment which has just got a Nobel prize. PIL was pursuing the malaria angle when they found that folk in those trials got arthritis relief.

    Extract

    Sales in New Zealand are exceeding budgets and growing. There has been
    a large increase in the average monthly sales since May 2015 when the company
    announced the positive preliminary clinical trial findings. Sales of the company’s
    flagship product Arthrem® have increased by more than 150% compared to the
    previous 12 month average monthly sales.
    The company has had some sales success in the United States but is awaiting
    publication of its clinical trial results before embarking on a concerted public relations
    campaign. The US e-commerce platform is fully operational and a soft launch in June
    exceeded budget. Promisia is testing various offerings in an effort to determine the
    most effective sales strategy. The US market represents the greatest opportunity
    for Promisia to increase revenues. The market is approximately 90 times larger
    than New Zealand and it carries with it a higher level of discretionary spending.

    http://www.promisia.com/financial-reports.

  12. #12
    Member
    Join Date
    Jun 2012
    Posts
    262

    Lightbulb

    Quote Originally Posted by artemis View Post
    Fur baby - common name for a pet treated like one of the family. I used it rather tongue in cheek to indicate that folk with fur babies often spend big on them, as they would for a human child.

    Subscription is for capsules.

    No, my user name is complete coincidence, and relates to the Greek myth. I am a shareholder, however, and was one long before this product was even thought of.

    The Principal Scientist at PIL said the Rheumatology Research Unit was very pleased with the results.

    As I type this, another coincidence, NBR Radio is broadcasting quite a lengthy item on PIL and Arthrem.
    Bit of action lately. Rights issue which was flagged has kept a lid on the price. But this will lift soon I guess. Quite a good announcement from the chairman yesterday confirming publication of the Clinical Trials in an international medical journal called Clinical Rheumatology. Those outfits are widely read and followed by the professionals. Due diligence should include visiting a pharmacy or two and just asking about the stuff.

  13. #13
    Senior Member
    Join Date
    Jun 2009
    Location
    Vancouver
    Posts
    668

    Default

    I think this will be a big year for PIL coming up . Turning cashflow positive, breaking into USA and Australia market on a bigger scale. Enough cash in the bank to get them on the way now for some serious growth.

  14. #14
    Member
    Join Date
    Jun 2012
    Posts
    262

    Thumbs up

    Quote Originally Posted by bung5 View Post
    I think this will be a big year for PIL coming up . Turning cashflow positive, breaking into USA and Australia market on a bigger scale. Enough cash in the bank to get them on the way now for some serious growth.
    You might be right Bung. They seem to be quietly achieving set targets that new management have set themselves. Promising....no pun intended.

  15. #15
    Senior Member
    Join Date
    Dec 2001
    Location
    Wellington, , New Zealand.
    Posts
    871

    Default

    Couple of updates from the recent annual shareholder meeting.

    A lot of effort has gone into supporting and upgrading the online global sales platform.

    Plenty of TV ads (using real people not actors) and this is boosting sales (revenue more than the ad spend). Good idea to trial in NZ which is usually regarded as a good test bed. Plus there was an article earlier this year about a young cyclist who took Arthrem with good results, and sales spiked.

    An independent pharmacy sales company told PIL recently that Arthrem was the fastest moving single product in pharmacies in the June quarter.

    Canine version of Arthrem not ready for release yet. So far only palatable for 70% of breeds, which is too low, they are working on it.

    PIL have stopped NZ pharmacies from selling Arthrem via their websites as the information given was not what PIL wanted) not sure why). Plus PIL margin is better if they sell direct from the PIL website. Seems like a mistake to me. Surely a problem which has been solved many times.

    Overall they are optimistic about revenue and thus share price. We'll see, but they do seem to be laying very good groundwork.

Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •